China NMPA Drug Inspection - Hebei Jiheng Pharmaceutical Co., Ltd. - Uncaria rhynchophylla (processed)

The Heilongjiang Provincial Food and Drug Administration announced on December 7, 2017, findings of non-compliance in traditional Chinese medicine pieces. Tests conducted by five drug testing institutions identified nine batches from five manufacturers as unqualified. The companies involved include Anhui Yishengtang Traditional Chinese Medicine Pieces Co., Ltd., Anhui Huadingtang Traditional Chinese Medicine Pieces Technology Co., Ltd., Hebei Jixintang Pharmaceutical Co., Ltd., Qiqihar Xianhe Traditional Chinese Medicine Pieces Processing Plant, and Harbin Runhe Traditional Chinese Medicine Pieces Processing Plant.

The primary issues stemmed from deficiencies in product appearance and other critical inspection parameters across various traditional Chinese medicines. In response, regulatory departments initiated immediate control measures, including sealing and seizing the affected batches. The implicated companies were mandated to cease sales and use of the non-compliant products, and to implement necessary corrective actions.

Operating under the *Drug Administration Law of the People's Republic of China* (Articles 73, 74, and 75), municipal food and drug administration departments are required to investigate the illegal distribution of these substandard drugs. They must publicly disclose the resolution for the selling entities within three months and promptly report the outcomes to the Provincial Bureau, ensuring adherence to quality standards and accountability.